Procept Biorobotics Showcases Aquablation Therapy as Next-Generation BPH Solution in Investor Presentation
Procept Biorobotics Corporation has unveiled an investor presentation emphasizing its Aquablation Therapy as a next-generation solution for benign prostatic hyperplasia (BPH). This automated waterjet technology aims to cater to various prostate sizes while enhancing safety and efficacy compared to traditional surgical methods. The presentation highlights a significant market opportunity, with over 8 million patients treated and a U.S. surgical market exceeding $20 billion. It also critiques pharmaceutical therapies for their limited symptom relief and potential side effects.
Procept Biorobotics Corporation has released a new investor presentation highlighting the company’s position in the benign prostatic hyperplasia (BPH) treatment market. The presentation outlines Aquablation Therapy as a unique, automated waterjet solution designed to address a wide range of prostate sizes and shapes, aiming to minimize the trade-off between safety and efficacy found in other surgical interventions. The company identifies a significant unmet need in the BPH market, noting over 8 million patients actively treated and an annual U.S. surgical market opportunity exceeding $20 billion. The presentation also discusses limitations of pharmaceutical therapies, citing minimal symptom relief and potential side effects such as ejaculatory dysfunction, erectile dysfunction, and increased risk of cardiac failure and dementia with long-term use. You can access the full presentation through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Procept Biorobotics Corporation published the original content used to generate this news brief on November 10, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
